Psychopharmacology

, Volume 88, Issue 4, pp 403–419 | Cite as

Acute dystonia induced by neuroleptic drugs

  • N. M. J. Rupniak
  • P. Jenner
  • C. D. Marsden
Review Article

Abstract

About 2.5% of patients treated with neuroleptic drugs develop acute dystonia within 48 h of commencing therapy. The symptoms remit on drug withdrawal or following anticholinergic therapy. Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man. In general, New World monkeys appear more susceptible to acute dystonia than Old World primates. It is at present not clear whether all primates, including man, would exhibit dystonia if a sufficiently high dose of neuroleptic was administered. Alternatively, some unknown, possibly species-specific or even genetic, factors may determine an individual's susceptibility to develop dystonia. Use of a rodent model of dystonia might enable more detailed analysis of biochemical correlates of dystonic behaviour. Whilst rodents do not exhibit overt dystonic behaviour after neuroleptic treatment, they may develop oral dyskinesias which bear a close pharmacological similarity to dystonia in man and primates. However, it is not known whether chewing induced by neuroleptic drugs in rats resembles acute dystonia in primates or whether this is another movement disorder possibly unique to rodent species. The pathophysiology of acute dystonia remains unknown, but may involve striatal dopaminergic and cholinergic function. In view of the close similarity between dystonia in man and other primates, studies on the mechanisms whereby neuroleptic drugs cause acute dystonic reactions in monkeys may give some clues to the pathogenesis of spontaneous dystonia in man.

Key words

Dystonia Neuroleptics Dyskinesia Animal models 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akindele O, Odejide AO (1976) Amodiaquine-induced involuntary movements. Br Med J 6029:214–215Google Scholar
  2. Anden NE (1972) Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol 24:905–906Google Scholar
  3. Anden NE, Butcher SG, Corrodi H (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314Google Scholar
  4. Ayd FJ (1960) Drug-induced extrapyramidal reactions: their clinical manifestations and treatment with akineton. Psychosomatics 1:143–150Google Scholar
  5. Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:1054–1060Google Scholar
  6. Bateman DN, Craft AW, Nicholson E, Pearson ADJ (1983) Dystonic reactions and the pharmacokinetics of metoclopramide in children. Br J Clin Pharmacol 15:557–559Google Scholar
  7. Bedard P, Delean J, Lafleur J, Larochelle L (1977) Haloperidol-induced dyskinesias in the monkey. Can J Neurol Sci 4:197–201Google Scholar
  8. Bhargava RK, Parakh LK, Hakim A, Gori MN, Bhardari NC (1973) Extra-pyramidal syndrome after antimalarials. J Assoc Physicions India 21:969–973Google Scholar
  9. Bowers MB, Rozitis A (1974) Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J Pharm Pharmacol 26:743–745Google Scholar
  10. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J (1982) Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology (NY) 32:1335–1346Google Scholar
  11. Casey DE, Denney D (1977) Pharmacological characterization of tardive dyskinesia. Psychopharmacology 54:1–8Google Scholar
  12. Casey DE, Gerlach J, Christensson A (1980) Dopamine, acetylcholine and GABA effects in acute dystonia in primates. Psychopharmacology 70:83–87Google Scholar
  13. Chadwick D, Reynolds EH, Marsden CD (1976) Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatr 39:1210–1218Google Scholar
  14. Christensen AV, Fjalland B, Moller Nielsen I (1976) On the super-sensitivity of dopamine receptors induced by neuroleptics. Psychopharmacology 48:1–6Google Scholar
  15. Cianchetti C, Masal C, Mangoni A (1978) Continuous apomorphine infusion in acute dystonic reactions to neuroleptics. Br J Psychiatry 133:284Google Scholar
  16. Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol 57:365–375Google Scholar
  17. Clow A, Theodorou A, Jenner P, Marsden CD (1980) Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63:145–157Google Scholar
  18. Cochlin E (1974) Dystonic reactions to metoclopramide and phenothiazines resembling tetanus. Br J Clin Pract 28:201–202Google Scholar
  19. Cools AR, Hendriks G, Korten J (1974) The acetylcholine-dopamine balance in the basal ganglia of rhesus monkeys and its role in dynamic, dystonic, dyskinetic, and epileptoid motor activities. J Neural Transm 36:91–105Google Scholar
  20. Costall B, Naylor RJ (1976) Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias. Eur J Pharmacol 36:423–429Google Scholar
  21. Delay J, Deniker P (1957) Caracteristiques neurophysiologiques des medicaments neuroleptiques. Rapport Symposium Internationale Medicaments Psychotropies, Milan 1957, In: Garratini S, Ghetti V (eds) Psychotropic drugs Elsevier, Amsterdam, pp 485–501Google Scholar
  22. Delay J, Deniker P (1968) Drug-induced extrapyramidal syndromes. In: Vinker PJ, Bruyn GW (eds) Handbook of clinical Neurology, vol 6, Diseases of the basal ganglia, Amsterdam, North-Holland, pp 248–266Google Scholar
  23. Delay J, Deniker P, Hare JM (1952) Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective (4560 RP). Annales Medicopsychologiques 110:112–117Google Scholar
  24. Deneau G, Crane GE (1969) Dyskinesia in rhesus monkeys tested with high doses of chlorpromazine. In: Crone GE, Gardner JR (eds) A multidisciplinary workshop: Psychotropic drugs and dysfunctions of the basal ganglia, Washington, Public Health Service Publications No. 1938, pp 12–14Google Scholar
  25. Deniker P, Ginestet D, Loo H (1980) Maniement des medicaments psychotropes. Doin Editeurs, ParisGoogle Scholar
  26. Deuel RK (1969) Neurological examination of rhesus monkeys treated with high doses of chlorpromazine. In: Crone GE, Gardner JR (eds) A multidisciplinary workshop: Psychotropic drugs and dysfunctions of the basal ganglia, Washington, Public Health Service Publication No. 1938, pp 15–18Google Scholar
  27. Dill RE, Nickey WM, Little MD (1968) Dyskinesias in rats following chemical stimulation of the neostriatum. Tex Rep Biol Med 26:101–106Google Scholar
  28. Doenecke AL, Heuermann RC (1980) Treatment of haloperidol abuse with diphenhydramine. Am J Psychiatry 137:487–488Google Scholar
  29. Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, Desai AB, Parikh MD, Rathi LG, Ghandi MH, Parikh RM, Thatte S, Bharaduraj J (1982) Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. J Clin Psychopharmacol 2:376–379Google Scholar
  30. Eldridge M (1970) The torsion dystonias: literature review and genetic and clinical studies. Neurology 20:1–78Google Scholar
  31. Elliot PNC, Jenner P, Chadwick D, Reynolds E. Marsden CD (1977) The effect of diphenylhydantoin on central catecholamine containing neuronal systems. J Pharm Pharmacol 29:41–43Google Scholar
  32. Gagrat D, Hamilton J, Belmaker RH (1978) Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 135:1232–1233Google Scholar
  33. Garver DL, Davis JM, Dekirmenjian H, Ericksen S, Gosengeld L, Haraszti J (1976) Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 47:199–201Google Scholar
  34. Gerlach J (1985) Pathophysiological mechanisms underlying tardive dyskinesia. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Psychopharmacology Supplement 2 Springer-Verlag, Berlin, pp 98–103Google Scholar
  35. Gessa R, Tagliamonte T, Gessa GL (1972) Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients. Lancet II:981–982Google Scholar
  36. Glassman RB, Glassman HN (1980) Oral dyskinesias in brain-damaged rats withdrawn from a neuroleptic: implications for models of tardive dyskinesia. Psychopharmacology 69:19–25Google Scholar
  37. Goldsmith RW (1959) Antidote for prochlorperazine intoxication in children. JAMA 170:361Google Scholar
  38. Groves JE, Mandel MR (1975) The long-acting phenothiazines. Arch Gen Psychiatry 32:893–900Google Scholar
  39. Gunne L-M, Barany S (1976) Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 50:237–240Google Scholar
  40. Gunne L-M, Barany S (1979) A monitoring testing for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacology 63:195–198Google Scholar
  41. Gunne L-M, Growdon J, Glaeser B (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134–139Google Scholar
  42. Haggstrom JE, Anderson U, Gunne LM (1981) A primate model for tardive dyskinesia: Postmortem biochemical findings. In: Perris C, Struwe G, Jansson B (eds) Developments in psychiatry, vol. 5, Biological psychiatry. Elsevier/North Holland, Biomedical Press, Amsterdam, pp 837–839Google Scholar
  43. Iversen SD, Howells RB, Hughes RP (1980) Behavioural consequences of long-term treatment with neuroleptic drugs. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics, Adv Biochem Psychopharmacol 24:305–313, Raven Press, New YorkGoogle Scholar
  44. Jeste DV, Wyatt RJ (1979) In search of treatment for tardive dyskinesia: review of the literature. Schiz Bull 5:251–293Google Scholar
  45. Jus K, Villeneuve A, Jus A (1972) Tardive dyskinesia and the rabbit syndrome during wakefulness and sleep. Am J Psychiatry 129:765Google Scholar
  46. Knights A, Okasha MS, Salih MA, Hirsch SR (1979) Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br J Psychiatry 135:515–523Google Scholar
  47. Kolbe H, Clow A, Jenner P, Marsden CD (1981) Neuroleptic induced acute dystonic reactions may be due to enhanced dopamine release onto supersensitive postsynaptic receptors. Neurology 31:434–439Google Scholar
  48. Kovacic B, Domino EF (1982) A monkey model of tardive dyskinesia (TD): Evidence that reversible TD may turn into irreversible TD. J Clin Psychopharmacol 2:305–307Google Scholar
  49. Liebman J, Neale R (1980) Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. Psychopharmacology 68:25–29Google Scholar
  50. Liebman J, Neale R, Moen NJ (1978) Differential behavioural effects of sulpiride in the rat and squirrel monkey. Eur J Pharmacol 50:377–383Google Scholar
  51. Lindqvist NG, Ullberg S (1972) The melanin affinity of chloroquine and chlorpromazine studied by whole body autoradiography. Acta Pharmacol Toxicol 3:(Suppl II)1–32Google Scholar
  52. Mackay AVP (1982) Antischizophrenic drugs. In: Tyrer PJ (ed) Drugs in Psychiatric Practice Butterworths, Cambridge, pp 42–81Google Scholar
  53. Marsden CD, Jenner P (1980) The pathophysiological basis of extrapyramidal movement disorders. Psychol Med 10:55–71Google Scholar
  54. Marsden CD, Mindham RHS, Mackay AVP (1985) Extrapyramidal movement disorders produced by antipsychotic drugs. In: Bradley PB, Hirsch SR (eds) The pharmacology and treatment of schizophrenia, Oxford University Press, London (in press)Google Scholar
  55. Marsden CD, Tarsy D, Baldessarini RJ (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurologic disease, Grune & Stratton, New York, pp 219–266Google Scholar
  56. Meldrum BS, Anlezark GM, Marsden CD (1977) Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain 100:313–326Google Scholar
  57. Mendez JS, Cotzias GC, Mena I, Parpavasiliou PS (1975) Diphenylhydantoin: blocking of levodopa effects. Arch Neurol 32:44–46Google Scholar
  58. Messiha FS (1974) The relationship of dopamine excretion to chlorpromazine induced dyskinesias in monkeys. Arch Int Pharmacodynam Ther 209:5–9Google Scholar
  59. Mones RJ (1973) Experimental dyskinesias in normal rhesus monkeys. In: Huntington's chorea, Advances in Neurology, vol. 1, Raven Press, New York, pp 665–669Google Scholar
  60. Murphey DL, Dill RE (1972) Chemical stimulation of discrete brain loci as a method of producing dyskinesia models in primates. Exp Neurol 34:244–254Google Scholar
  61. Neale R, Gerhardt S, Fallon S, Liebman JM (1982) Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys. Psychopharmacology 77:223–228Google Scholar
  62. Neale R, Gerhardt S, Liebman JM (1984) Effects of dopamine agonists, catecholamine depletors, and cholinergic and GA-BAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology 82:20–26Google Scholar
  63. Parkes JD, Bedard P, Marsden CD (1976) Chorea and torsion in Parkinsonism. Lancet 1:155Google Scholar
  64. Paulson GW (1973) Dyskinesias in monkeys. In: Huntington's chorea, Advances in Neurology, vol. 1, Raven Press, New York, pp 647–650Google Scholar
  65. Porsolt RD, Jalfre M (1981) Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology 75:16–21Google Scholar
  66. Pycock C, Dawbarn D, O'Shaughnessy C (1982) Behavioral and biochemical changes following chronic administrations of l-dopa to rats. Eur J Pharmacol 79:201–215Google Scholar
  67. Ramsden PD, Frogatt DL (1972) Idiosyncratic responses to phenothiazines. Br Med J 1–246Google Scholar
  68. Reches A, Burke RE, Traub M, Ilson J, Swash M, Fahn S (1985). Tetrabenazine induces acute dystonic reactions. Neurology (NY) (in press)Google Scholar
  69. Rotrosen J, Stanley J, Kuhn C, Wazer D, Gershon S (1980) Experimental dystonia induced by quaternary-chlorpromazine. Neurology 30:878–881Google Scholar
  70. Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats. Psychopharmacology 79:226–230Google Scholar
  71. Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterisation of purposeless chewing movements in rats. Psychopharmacology 85:71–79Google Scholar
  72. Sarwar-Foner GJ (1960) Recognition and management of drug-induced extrapyramidal reactions and “paradoxical” behavioural reactions in psychiatry. Can Med Assoc J, 83:312–318Google Scholar
  73. Sassin JF (1975) Drug-induced dyskinesia in monkeys. In: Meldrum BS, Marsden CD (eds) Primate models of neurological disorders, Advances in Neurology, vol. 1, Raven Press, New York, pp 47–54Google Scholar
  74. Scatton B, Glowinski J, Julou L (1976) Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administration of neuroleptics. Brain Res 109:184–189Google Scholar
  75. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:230–313Google Scholar
  76. Sethy VH, van Woert MH (1974) Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Commun Chem Pathol Pharmacol 8:13–28Google Scholar
  77. Sigwald J, Bouttier D, Raymondeaud C, Piot C (1959) Quatre cas de dyskinesie facio-bucco-linguo-maticatrice a evolution prolongee secondare a un traitement par les neuroleptiques. Review Neurol (Paris) 100:751–755Google Scholar
  78. Singhi S, Singhi P, Singh I (1977) Chloroquine-induced involuntary movements. Br Med J 6085:520Google Scholar
  79. Spillane JD, Spillane JA (1982) An atlas of clinical neurology 3rd Edition, Oxford University Press, OxfordGoogle Scholar
  80. Steck H (1984) Le syndrome extrapyramidal et diencephalique au cours des traitments au Largactil et au Serpasil. Ann Med Psychol 112:737–743Google Scholar
  81. Stockhausen FG (1960) Clinical studies with tetrabenazine (RO 1–9569). Dis Nerv Syst 21:321–328Google Scholar
  82. Swett C (1975) Drug-induced dystonia. Am J Psychiatry 132:532–534Google Scholar
  83. Thach BT, Chase TN, Bosman JF (1975) Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. New Engl J Med 293:486–487Google Scholar
  84. Tune L, Coyle JT (1981) Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 75:9–15Google Scholar
  85. Umez-Eronini E, Eronini EA (1977) Chloroquine-induced involuntary movements. Br Med J 6066:945–946Google Scholar
  86. Uhrbrand L, Faurbye A (1960) Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacology 1:408–419Google Scholar
  87. Villeneuve A (1972) The rabbit syndrome, a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 17:5569Google Scholar
  88. Waddington JL, Gamble SJ (1980) Emergence of apomorphine-induced ‘vacuous chewing’ during 6 months continuous treatment with fluphenazine decanoate. Eur J Pharmacol 68:387–388Google Scholar
  89. Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532Google Scholar
  90. Walinder J, Skott A, Carlsson A, Roos B-E (1976) Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. Arch Gen Psychiatry 33:501–505Google Scholar
  91. Weiss B, Santelli S, Lusink G (1977) Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology 53:289–293Google Scholar
  92. Yamada K, Furukawa T (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67:39–43Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • N. M. J. Rupniak
    • 1
  • P. Jenner
    • 1
  • C. D. Marsden
    • 1
  1. 1.MRC Movement Disorders Research GroupUniversity Department of Neurology, and Parkinson's Disease Society Research Centre, Institute of Psychiatry & King's College Hospital Medical SchoolLondonUK

Personalised recommendations